By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Nxt2b has signed an agreement to purchase 49 percent of all outstanding shares of Swedish protein and molecular technologies firm Olink Bioscience for an undisclosed amount.

The deal is expected to "accelerate the growth and value creation of the company by injecting knowledge, experience, and financial strength to complement Olink's unique product and technology position," Olink said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.